- Genelux entered a sales agreement with TD Cowen to offer and sell common stock with aggregate gross proceeds of up to USD 100 million.
- Shares may be sold from time to time through at-the-market transactions, including block trades.
- TD Cowen will receive compensation of up to 3% of the gross proceeds from any shares sold under the agreement.
- Net proceeds are intended for general corporate purposes, including research and development and clinical trial expenses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011649), on March 19, 2026, and is solely responsible for the information contained therein.
Comments